According to a newly published market research report by 24LifeSciences, global plaque psoriasis treatment market was valued at USD 12.4 billion in 2024 and is projected to reach USD 21.9 billion by 2032, growing at a compound annual growth rate (CAGR) of 7.2% during the forecast period 20252032.
Plaque psoriasis, the most common form affecting 80-90% of psoriasis patients, is a chronic autoimmune disorder characterized by raised, inflamed skin lesions covered with silvery-white scales. The market encompasses topical therapies, phototherapy, systemic medications, and biologic drugs that target specific immune pathways. Recent advances in IL-17/23 inhibitors and JAK inhibitors have transformed treatment paradigms for moderate-to-severe cases.
Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/15876/plaque-psoriasis-treatment-market
Growing Disease Burden and Treatment Accessibility Drive Market Expansion
The market growth primarily stems from the rising global prevalence of psoriasis, affecting approximately 125 million people worldwide (2-3% of population). Increased disease awareness and improved diagnostic capabilities have expanded the treated patient pool, particularly in developing regions. The introduction of highly effective biologic therapies that achieve PASI 90 (90% skin clearance) in 50-60% of patients has revolutionized treatment expectations.
Furthermore, expanding insurance coverage for biologics in developed markets and the establishment of patient assistance programs have improved treatment accessibility. The market also benefits from increased dermatology specialization and the growing adoption of multidisciplinary treatment approaches addressing both physical symptoms and psychosocial impacts.
Biologic Therapies Transforming Treatment Paradigms
Biologic drugs now dominate the moderate-to-severe plaque psoriasis treatment landscape, accounting for over 40% market share. These targeted immunotherapies demonstrate superior efficacy over traditional systemic treatments, with newer IL-17/23 inhibitors showing unprecedented response rates. The development pipeline remains robust, with 50+ novel compounds in clinical trials exploring innovative mechanisms like T-cell modulation and JAK-STAT pathway inhibition.
Recent FDA approvals including deucravacitinib (2022) the first oral TYK2 inhibitor highlight the industry's shift toward convenient administration formats. The market is also seeing increased adoption of personalized treatment algorithms that match patients with optimal therapies based on disease characteristics and comorbidities.
Market Challenges: Cost Barriers and Treatment Gaps
Despite impressive growth, the market faces significant challenges:
-
High treatment costs with biologics averaging $50,000-$75,000 annually
-
Limited access in developing regions due to infrastructure and affordability constraints
-
30% of patients show inadequate response to current biologics
-
Safety concerns with long-term immunosuppression
Additionally, the anticipated patent expirations of major biologics through 2025-2030 are expected to introduce biosimilar competition, potentially reducing prices by 25-40% while creating reimbursement challenges.
Get the Complete Report & Table of Contents: https://www.24lifesciences.com/plaque-psoriasis-treatment-market-15876
North America Leads Global Market with Advanced Treatment Adoption
The North American region dominates the plaque psoriasis treatment market, holding 48% revenue share, driven by:
-
High biologic adoption rates and favorable reimbursement policies
-
Strong R&D investment and rapid adoption of novel therapies
-
Extensive specialist networks and patient support programs
-
Growing emphasis on patient-reported outcomes and quality-of-life measures
Europe follows as the second-largest market with universal healthcare systems supporting treatment access, while Asia-Pacific shows the highest growth potential (8.2% CAGR) due to improving healthcare infrastructure and rising disease awareness.
Specialty Dermatology Centers Emerge as Key Treatment Settings
By application, specialty dermatology centers are becoming the preferred treatment venues, offering comprehensive care including phototherapy and biologic infusion capabilities. The shift toward value-based care models emphasizes the importance of specialized centers that can deliver optimal outcomes through coordinated, multidisciplinary approaches.
By product type, biologic therapies now lead the market, though topical treatments retain importance for mild cases and combination regimens. The recent introduction of advanced oral small molecule therapies is creating new sub-segments with projected 12% annual growth.
Competitive Landscape: Innovation-Driven Biopharma Dominance
The market features a moderately consolidated competitive environment, with the top five companies controlling over 60% market share through blockbuster biologics. Innovation remains the key differentiator, as companies race to develop next-generation therapies with improved efficacy and convenience.
Key companies profiled in the report include:
-
AbbVie (Skyrizi, Humira)
-
Johnson & Johnson (Tremfya, Stelara)
-
Novartis (Cosentyx)
-
Eli Lilly (Taltz)
-
Amgen (Enbrel, Otezla)
-
UCB (Bimzelx)
-
Bristol-Myers Squibb (Sotyktu)
-
and More
Get the Complete Report & Table of Contents:
https://www.24lifesciences.com/plaque-psoriasis-treatment-market-15876
Emerging Opportunities in Personalized Medicine and Digital Health
The market presents significant growth potential through personalized treatment approaches based on biomarkers and genetic profiling. Digital health innovations, including telemedicine platforms and connected drug delivery systems, are creating new care models that improve adherence and outcomes.
Emerging economies offer untapped potential as healthcare infrastructure improves and awareness grows. Local production of biosimilars and innovative partnership models between pharma companies and healthcare providers are expected to enhance treatment accessibility in these markets.
Access the Full Report
Download a Free Sample Report (PDF):
https://www.24lifesciences.com/download-sample/15876/plaque-psoriasis-treatment-market
Get the Complete Report & Table of Contents:
https://www.24lifesciences.com/plaque-psoriasis-treatment-market-15876
About 24LifeSciences
24LifeSciences is a leading provider of market intelligence and strategic research reports across pharmaceuticals, biotechnology, medical devices, and healthcare technologies. Our reports are designed to support data-driven decision-making for manufacturers, healthcare providers, investors, consultants, and policy makers worldwide.
Facebook Conversations
Disqus Conversations